You are here

  • Home
  • Archive
  • Volume 66, Issue Suppl 2
  • OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

Citation Tools

Article menu
Download PDFPDF
IBD Section Free Papers
OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Keshav S, Goh J, Hart A, et al
OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn’s disease: results from the phase ii fitzroy study
Gut 2017;66:A25.